Subhashish Agarwal, MD
Cardiovascular Disease · Brookfield, WINPI 1134173875
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,411 of the $377,637 with a category attached, or 84.8%. Johnson & Johnson accounts for 81.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $126,608 and has fallen 93.3% since, to $8,506 in 2025. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 596 payments — averaging $633.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$307K
- AstraZeneca$41K
- Novartis$14K
- Pfizer$5K
- Bayer$4K
- Bridgebio Pharma, Inc.$3K
- plus $4K from 18 others
What the payments were for
- Consulting fees$13,1393%
- Speaking & faculty fees$320,41185%
- Travel & lodging$27,0957%
- Food & beverage$16,8704%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 315 | $307,480 |
| AstraZeneca | 92 | $40,951 |
| Novartis | 59 | $13,672 |
| Pfizer | 43 | $4,705 |
| Bayer | 7 | $4,170 |
| Bridgebio Pharma, Inc. | 3 | $3,000 |
| Chiesi USA, Inc. | 2 | $1,215 |
| Novo Nordisk | 7 | $453 |
| E.r. Squibb & Sons, L.L.C. | 19 | $402 |
| Amgen | 13 | $334 |
| Alnylam Pharmaceuticals Inc. | 4 | $269 |
| Esperion Therapeutics, Inc. | 2 | $175 |
| Janssen Scientific Affairs, LLC | 2 | $154 |
| Boston Scientific | 3 | $122 |
| Merck | 4 | $94 |
| Boehringer Ingelheim | 5 | $84 |
| Daiichi Sankyo Inc. | 3 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Heartflow, Inc. | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Cvrx, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$377,637 in reported general payments places this provider in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 85 | $113,161 |
| EliquisApixaban | 81 | $108,820 |
| FarxigaDapagliflozin Propanediol | 93 | $104,646 |
| EntrestoSacubitril/Valsartan | 33 | $60,085 |
| JardianceEmpagliflozin | 25 | $27,270 |
| BrilintaTicagrelor | 21 | $25,115 |
| VascepaIcosapent Ethyl | 26 | $19,160 |
| Praluent PenAlirocumab | 12 | $13,358 |
| OzempicSemaglutide | 12 | $11,326 |
| Metoprolol Succinate | 302 | $4,840 |
| Atorvastatin Calcium | 347 | $3,611 |
| Ezetimibe | 93 | $2,069 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $1,225 |
| Icosapent Ethyl | 12 | $1,204 |
| Rosuvastatin Calcium | 76 | $1,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $40,951 | $129,762114 claims |
| Johnson & JohnsonXarelto | $307,480 | $113,16185 claims |
| PfizerEliquis | $4,705 | $108,82081 claims |
| NovartisEntresto | $13,672 | $60,08533 claims |
| Boehringer IngelheimJardiance | $84 | $27,27025 claims |
| Novo NordiskOzempic | $453 | $11,32612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Brookfield
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
- David Luddenla Crosse$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.